Conditions:   Genetics;   Metabolism;   Type 2 Diabetes
Interventions:   Other: Mixed Meal Tolerance Test;   Drug: Metformin
Sponsors:   Massachusetts General Hospital;   Instituto Carlos Slim de la Salud;   Broad Institute of Harvard and MIT
Not yet recruiting - verified March 2014

Condition:   Polycystic Ovary Syndrome
Intervention:   Drug: Metformin
Sponsor:   Mayo Clinic
Recruiting - verified March 2014

Condition:   Healthy
Interventions:   Drug: Linagliptin;   Drug: Metformin;   Drug: Linagliptin/Metformin FDC;   Drug: Linagliptin/Metformin FDC;   Drug: Linagliptin/Metformin FDC;   Drug: Linagliptin;   Drug: Metformin;   Drug: Metformin;   Drug: Linagliptin/Metformin FDC;   Drug: Linagliptin;   Drug: Metformin;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Not yet recruiting - verified March 2014

Condition:   Healthy
Interventions:   Drug: Linagliptin/Metformin ER FDC;   Drug: Linagliptin;   Drug: Linagliptin;   Drug: Linagliptin/Metformin ER FDC;   Drug: Linagliptin;   Drug: Metformin ER;   Drug: Linagliptin/Metformin ER FDC;   Drug: Metformin ER;   Drug: Linagliptin/Metformin ER FDC;   Drug: Metformin ER;   Drug: Metformin ER;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Not yet recruiting - verified March 2014

Condition:   Head and Neck Squamous Cell Cancer
Intervention:   Drug: Metformin
Sponsor:   Thomas Jefferson University
Recruiting - verified March 2014

Condition:   Healthy
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Metformin XR, 500 mg;   Drug: CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg;   Drug: CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg
Sponsor:   Janssen Research & Development, LLC
Not yet recruiting - verified February 2014

Conditions:   Type 2 Diabetes;   Vitamin B12 Deficiency;   Neuropathy;   Anemia
Interventions:   Behavioral: Office visit intervention;   Behavioral: Electronic Message Intervention
Sponsor:   Ohio State University
Enrolling by invitation - verified February 2014

Condition:   Healthy Volunteers
Interventions:   Drug: Canagliflozin, 300 mg;   Drug: Metformin XR, 500 mg;   Drug: CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg;   Drug: CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg
Sponsor:   Janssen Research & Development, LLC
Not yet recruiting - verified February 2014

Condition:   Healthy
Interventions:   Drug: Canagliflozin, 300 mg;   Drug: Metformin XR, 500 mg;   Drug: CANA/MET XR FDC, Formulation 1, 150 mg/500;   Drug: CANA/MET XR FDC, Formulation 2, 150 mg/500 mg
Sponsor:   Janssen Research & Development, LLC
Not yet recruiting - verified March 2014

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Glimepiride;   Drug: Metformin;   Drug: Pioglitazone;   Drug: Acarbose;   Drug: Linagliptin;   Drug: Sitagliptin;   Drug: Liraglutide;   Drug: Insulin Glargine;   Drug: Exenatide once weekly (QW);   Drug: Exenatide twice daily (BID)
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified February 2014

Condition:   Type 2 Diabetes
Interventions:   Drug: HM11260C;   Drug: Placebo
Sponsor:   Hanmi Pharmaceutical Company Limited
Recruiting - verified March 2014

Condition:   Diabetes
Interventions:   Drug: SYR-322 + metformin hydrochloride;   Drug: SYR-322 + metformin hydrochloride;   Drug: SYR-322 + metformin hydrochloride placebo
Sponsor:   Takeda
Not yet recruiting - verified February 2014

Condition:   Healthy Volunteers
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Metformin XR, 500 mg;   Drug: CANA/MET XR FDC, Formulation 1, 50 mg/500 mg;   Drug: CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Sponsor:   Janssen Research & Development, LLC
Not yet recruiting - verified February 2014

Condition:   Type 2 Diabetes
Interventions:   Drug: Metformin glycinate;   Drug: Metformin Hydrochloride
Sponsors:   Laboratorios Silanes S.A. de C.V.;   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Not yet recruiting - verified February 2014

Conditions:   Endometrial Adenocarcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions:   Drug: paclitaxel;   Drug: carboplatin;   Drug: metformin hydrochloride;   Other: placebo;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Not yet recruiting - verified February 2014

Condition:   Infection, Human Immunodeficiency Virus
Interventions:   Drug: Metformin 500 mg q12h;   Drug: Dolutegravir 50 mg q24h;   Drug: Dolutegravir 50 mg q12h
Sponsors:   ViiV Healthcare;   GlaxoSmithKline
Not yet recruiting - verified February 2014

Condition:   Obesity
Interventions:   Drug: metformin;   Dietary Supplement: Conjugated Linoleic Acid;   Drug: Placebo;   Behavioral: Healthy habits program
Sponsors:   Laboratorios Silanes S.A. de C.V.;   Hospital General de Mexico
Recruiting - verified February 2014

Condition:   Diabetes
Interventions:   Drug: linagliptin;   Drug: insulin glargine
Sponsors:   Emory University;   American Diabetes Association
Not yet recruiting - verified February 2014

Conditions:   Cushing's Disease,;   Acromegaly
Interventions:   Drug: Pasireotide s.c.;   Drug: Sitagliptin;   Drug: Liraglutide;   Drug: Insulin;   Drug: Pasireotide LAR;   Drug: Metformin
Sponsors:   Novartis;   Novartis Pharmaceuticals
Not yet recruiting - verified February 2014

Condition:   Type 2 Diabetes
Interventions:   Drug: Insulin glargine/lixisenatide HOE901/AVE0010;   Drug: Insulin glargine HOE901;   Drug: Lixisenatide AVE0010;   Drug: Metformin
Sponsor:   Sanofi
Not yet recruiting - verified February 2014